Literature DB >> 25394974

[Inflammation as molecular target in chondrosarcoma].

T Kalinski1.   

Abstract

Inflammation is a hallmark in the development and progression of malignant tumors. In chondrosarcoma the inflammatory changes are relatively discrete; however, tumor-associated macrophages (TAM) may exert tumor-promoting effects. Interleukin (IL)-1 is an inflammatory cytokine which is produced by TAMs and which leads to the expression of NF-κB-regulated genes in chondrosarcoma cells, such as vascular endothelial growth factor A (VEGF-A). Through IL-1 antagonists and substances, such as curcumin IL-1-induced VEGF-A expression and angiogenesis can be blocked; therefore, IL-1-blockade provides an interesting therapy target for chondrosarcoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25394974     DOI: 10.1007/s00292-014-1968-1

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  21 in total

1.  ADAMTS1 is regulated by interleukin-1beta, not by hypoxia, in chondrosarcoma.

Authors:  Thomas Kalinski; Sabine Krueger; Saadettin Sel; Kerstin Werner; Martin Röpke; Albert Roessner
Journal:  Hum Pathol       Date:  2006-08-01       Impact factor: 3.466

2.  Establishment and characterization of the permanent human cell line C3842 derived from a secondary chondrosarcoma in Ollier's disease.

Authors:  Thomas Kalinski; Sabine Krueger; Antje-Friederike Pelz; Peter Wieacker; Roland Hartig; Martin Röpke; Regine Schneider-Stock; Frank Dombrowski; Albert Roessner
Journal:  Virchows Arch       Date:  2005-02-25       Impact factor: 4.064

Review 3.  Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes.

Authors:  Alberto Mantovani; Silvano Sozzani; Massimo Locati; Paola Allavena; Antonio Sica
Journal:  Trends Immunol       Date:  2002-11       Impact factor: 16.687

4.  Curcumin blocks interleukin-1 (IL-1) signaling by inhibiting the recruitment of the IL-1 receptor-associated kinase IRAK in murine thymoma EL-4 cells.

Authors:  Nadine Jurrmann; Regina Brigelius-Flohé; Gaby-Fleur Böl
Journal:  J Nutr       Date:  2005-08       Impact factor: 4.798

Review 5.  Bioavailability of curcumin: problems and promises.

Authors:  Preetha Anand; Ajaikumar B Kunnumakkara; Robert A Newman; Bharat B Aggarwal
Journal:  Mol Pharm       Date:  2007-11-14       Impact factor: 4.939

Review 6.  Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions.

Authors:  Ron N Apte; Yakov Krelin; Xiaoping Song; Shahar Dotan; Eli Recih; Moshe Elkabets; Yaron Carmi; Tatyana Dvorkin; Roslayn M White; Lubov Gayvoronsky; Shraga Segal; Elena Voronov
Journal:  Eur J Cancer       Date:  2006-03-10       Impact factor: 9.162

Review 7.  Why not treat human cancer with interleukin-1 blockade?

Authors:  Charles A Dinarello
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

Review 8.  Highly active anticancer curcumin analogues.

Authors:  Cara A Mosley; Dennis C Liotta; James P Snyder
Journal:  Adv Exp Med Biol       Date:  2007       Impact factor: 2.622

9.  Heterogeneity of angiogenesis and blood vessel maturation in cartilage tumors.

Authors:  Thomas Kalinski; Saadettin Sel; Irina Kouznetsova; Martin Röpke; Albert Roessner
Journal:  Pathol Res Pract       Date:  2009-01-20       Impact factor: 3.250

Review 10.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

View more
  2 in total

1.  IL-1RA suppresses esophageal cancer cell growth by blocking IL-1α.

Authors:  Sui Chen; Zhimin Shen; Zhun Liu; Lei Gao; Ziyang Han; Shaobin Yu; Mingqiang Kang
Journal:  J Clin Lab Anal       Date:  2019-05-17       Impact factor: 2.352

2.  Clival Chondrosarcoma Associated With an Intra-Axial Cystic Medullary Lesion Responsive to Steroids.

Authors:  Johannes Walter; Sandra Kapitza; Niklaus Krayenbühl; Alexander A Tarnutzer
Journal:  Front Neurol       Date:  2018-06-26       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.